EASD: SGLT2 inhibitor empagliflozin cuts CV risk in patients with type 2 diabetesSeptember 18, 2015DiabetesLipid Disorders
No difference in long-term cost for diabetes treatment with bariatric surgerySeptember 17, 2015DiabetesObesity
Long-acting basal insulin controls HbA1c as well as glargineSeptember 16, 2015DiabetesLipid Disorders
EASD: Intranasal glucagon reverses hypoglycemia in children and adolescentsSeptember 16, 2015DiabetesPediatrics
ESC: Further data indicate no excess heart failure risk with lixisenatide or sitagliptinSeptember 13, 2015Diabetes
FDA issues revised warning for adverse effects associated with canagliflozinSeptember 10, 2015DiabetesOsteoporosis
